The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data.

Autor: Reddy SR; Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA., Chang E; Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA., Tarbox MH; Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA., Broder MS; Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA., Tieu RS; Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA., Guthrie S; Akcea Therapeutics, Boston, MA, USA., Vera-Llonch M; Akcea Therapeutics, Boston, MA, USA. mverallonch@akceatx.com., Pollock MR; Akcea Therapeutics, Boston, MA, USA.
Jazyk: angličtina
Zdroj: Neurology and therapy [Neurol Ther] 2020 Dec; Vol. 9 (2), pp. 473-482. Date of Electronic Publication: 2020 May 25.
DOI: 10.1007/s40120-020-00194-4
Abstrakt: Introduction: Little is known about the burden of hereditary transthyretin (ATTRv) amyloidosis, a genetic, progressive, and fatal disease caused by extracellular deposition of transthyretin amyloid fibrils. The study's aim was to estimate costs and disease burden associated with ATTRv amyloidosis in a real-world setting.
Methods: Using IBM ® MarketScan ® Commercial and Medicare Supplemental data, we identified patients at least 18 years of age with newly diagnosed ATTRv amyloidosis. Diagnosis required at least one medical claim with relevant diagnosis code (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] 277.30-.31, 277.39; ICD-10-CM E85.0-.4, E85.89, E85.9) between January 1, 2014 and December 31, 2016, and at least one additional criterion occurring during study period (2013-2017): at least 15 days diflunisal use without more than a 30-day gap; liver transplant; or claim with codes E85.1 or E85.2. First diagnosis date was study index. Continuous enrollment 1-year pre-index (baseline) and post-index (follow-up) was required. Patients with baseline amyloidosis diagnosis were excluded. Outcomes of interest were comorbidities and 1-year follow-up healthcare utilization and costs (also reported quarterly).
Results: Among 185 qualifying patients, mean age was 59.2 years (standard deviation 15.2), 54.1% were female, and baseline Charlson comorbidity index was 2.2 (2.5). Neuropathy (30.3%), diabetes (27.0%), and cardiovascular-related comorbidities, including dyspnea (25.9%) and congestive heart failure (21.6%), were common during follow-up. Nearly a quarter of patients (24.9%) were hospitalized during follow-up. Most hospitalizations and emergency department visits occurred in the first quarter post-diagnosis (18.9%, 17.8%, respectively) and dropped in subsequent quarters. The annual mean total cost was $64,066, with inpatient services contributing the majority of the expenses ($34,461), followed by outpatient ($23,853), and then pharmacy ($5752). As with utilization, costs were highest in the first quarter post-diagnosis and dropped in subsequent quarters.
Conclusion: Patients newly diagnosed with ATTRv amyloidosis have substantial healthcare utilization and costs in the first year, primarily the initial months, post-diagnosis. Further research should examine later costs associated with disease progression and end-of-life care.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje